Ipamorelin

In the clinical treatment of growth hormone deficiency, growth hormone-releasing peptide drugs provide patients with a milder alternative solution due to their precise action targets. Ipamorelin belongs to growth hormone secretagogue receptor agonists. It can specifically stimulate the pulsatile secretion of endogenous growth hormone by binding to the GHSR-1a receptors in the pituitary gland and hypothalamus, without disrupting the feedback regulation mechanism of endogenous hormones. At present, this ingredient is mainly used for the replacement therapy of adult growth hormone deficiency, and can also assist in improving the clinical symptoms of related disorders such as children's growth retardation and sarcopenia. The applicable population covers relevant patients in the departments of pediatrics, endocrinology and geriatrics.

The global market size related to ipamorelin was approximately USD 120 million in 2023, and it is expected to continue growing at a compound annual growth rate of 7.2% from 2024 to 2030. The growth momentum mainly comes from the expansion of treatment demand for adult endocrine disorders and the exploration in the field of elderly muscle health management. The current market supply is dominated by compliant API manufacturers in Europe and India, while domestic manufacturers are in the stage of application and layout. There are no relevant preparation varieties included in the centralized procurement catalog, and the market is still in a blue ocean stage of competition.

The original research enterprise of ipamorelin is Theratechnologies, a US company, with the original brand name Egrifta SV. Its core compound patent in the United States expired in 2021, and the compound patent in China expired in 2022. The main dosage form approved for the original product is powder for injection, with specifications of 1.5 mg/vial and 2.0 mg/vial, which has been included in the FDA Reference Listed Drug Catalog. No original preparation has been approved for marketing in China yet. As of now, no ipamorelin API registration number in valid status has been found on the CDE API registration platform, and no domestic preparation has been approved. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of ipamorelin impurity reference standards, most of which are available in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for API R&D, quality research and preparation application links.